Environmental

ZYME’s very high R&D intensity supports a science-led footprint, but peer-relative environmental benefits are limited because most biotech peers also operate low-manufacturing, low-emissions models.

The company’s asset-light operating profile likely constrains direct Scope 1 and 2 exposure versus industrial peers, yet this is broadly typical across the biotechnology peer set.

No disclosed environmental targets, emissions metrics, or climate-transition disclosures were provided, leaving peer-relative environmental transparency harder to verify than for better-disclosing peers.

Environmental risk appears more concentrated in laboratory waste, energy use, and supply-chain controls than in heavy industrial emissions, which keeps the profile moderate versus peers.

Social

ZYME’s elevated stock-based compensation to revenue suggests meaningful reliance on equity incentives, which can support retention but may dilute perceived employee alignment versus peers.

High R&D spending indicates dependence on specialized scientific talent, making workforce continuity and safety practices material social factors relative to other biotech companies.

No human-capital, diversity, safety, or community-impact disclosures were provided, so social transparency appears less complete than at peers with broader ESG reporting.

As a clinical-stage biotech, patient and trial-governance expectations are material, but the available data do not show a clear social advantage over peer companies.

Governance

ZYME’s low debt-to-equity ratio indicates conservative balance-sheet governance, but peer-relative governance strength is limited because biotech peers often also carry modest leverage.

The extremely high net debt-to-EBITDA metric is not economically meaningful for a loss-making biotech, yet it highlights that leverage-based governance signals are less informative than peers with stable earnings.

Stock-based compensation at 58.6% of revenue points to heavy dilution pressure, which can weaken capital-discipline perception versus better-aligned peers.

No board, audit, ethics, or executive-compensation disclosures were provided, so governance assessment remains constrained and cannot be scored above moderate versus peers.

Overall Score

ZYME ranks as a moderate ESG performer versus biotech peers because its low-emissions operating model is offset by limited disclosure depth and dilution-heavy capital practices.

Score Driver: Limited ESG Disclosure And Capital-Discipline Transparency Versus Peers